Observational Prospective Study on Patients Treated With Norditropin®

Condition(s) targeted: Growth Hormone Deficiency (GHD); Growth Hormone Deficiency, Adults (GHDA); Turner Syndrome; Small for Gestational Age (SGA); Chronic Renal Insufficiency; Noonan Syndrome

Intervention: somatropin (Drug); somatropin (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Novo Nordisk

Official(s) and/or principal investigator(s):
Viatcheslav Rakov, MD, Study Director, Affiliation: Novo Nordisk Health Care AG

Overall contact:
Public Access to Clinical Trials - Novo Nordisk, Phone: Please Contact NN via email, Email: clinicaltrials@novonordisk.com

This study is conducted in Europe. The aim of this observational study is to investigate the effectiveness and safety of real-life treatment with Norditropin®. The study population will consist of children and adults who are already being treated with Norditropin® or who are candidates for treatment with Norditropin®.

Official title: NordiNet® International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin®

Study design: Cohort, Prospective

Primary outcome:

Effect of Norditropin® treatment on height gain (change in height) in children

Effect of Norditropin® treatment on body weight and body composition in adults

Secondary outcome:

Effect of Norditropin® treatment on glucose metabolism, body weight, blood biochemistry, bone age, primary tumour occurrence or reoccurrence, the endocrine system and pubertal development in children

Effect of Norditropin® treatment on quality of life, glucose metabolism, tumour status, blood biochemistry and the endocrine system in adults

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Judged by the physician as per the Norditropin® label

Exclusion Criteria:

- Judged by the physician as per the Norditropin® label

Public Access to Clinical Trials - Novo Nordisk, Phone: Please Contact NN via email, Email: clinicaltrials@novonordisk.com

Prague 16000, Czech Republic; Recruiting

Copenhagen S 2300, Denmark; Recruiting

Espoo FI-02600, Finland; Recruiting

Paris La défense cedex 92936, France; Recruiting

Mainz 55127, Germany; Recruiting

Budapest H-1025, Hungary; Recruiting

Rome 00144, Italy; Recruiting

Vilnius 08119, Lithuania; Recruiting

Alphen a/d Rijn, Netherlands; Recruiting

Rud 1309, Norway; Recruiting

Moscow 119330, Russian Federation; Recruiting

Belgrade 11 070, Serbia; Recruiting

Ljubljana SI-1000, Slovenia; Recruiting

Malmö SE-202 15, Sweden; Recruiting

Zurich, Oerlikon CH-8050, Switzerland; Recruiting

Crawley, West Sussex RH11 9RT, United Kingdom; Recruiting

Clinical Trials at Novo Nordisk

Starting date: April 2006
Ending date: March 2011
Last updated: August 14, 2009